Abstract
The COVID-19 pandemic is caused by the betacoronavirus SARS-CoV-2. In November 2021, the Omicron variant was discovered and classified as a variant of concern (VOC). Omicron shows substantially more mutations in the spike protein than any previous variant, mostly in the receptor binding domain (RBD). We analyzed the binding of the Omicron RBD to the human ACE2 receptor (hACE2) and the ability of human sera from COVID-19 patients or vaccinees in comparison to Wuhan, Beta or Delta RBDs variants.
All RBDs were produced in insect cells. RBD binding to hACE2 was analyzed by ELISA and microscale thermophoresis (MST). Similarly, sera from 27 COVID-19 patients, 58 fully vaccinated individuals and 16 booster recipients were titrated by ELISA on the fixed RBDs from the original Wuhan strain, Beta, Delta and Omicron VOC.
Surprisingly, the Omicron RBD showed a weaker binding to ACE2 compared to Beta and Delta, arguing that improved ACE2 binding is not a likely driver of Omicron evolution. Serum antibody titers were significantly lower against Omicron RBD compared to the original Wuhan strain. However, a difference of 2.5 times was observed in RBD binding while in other studies the neutralization of Omicron SARS-CoV-2 was reduced by a magnitude of 10x and more. These results indicate an immune escape focused on neutralizing antibodies.
The reduced binding of sera to Omicron RBD adds evidence that current vaccination protocols may be less efficient against the Omicron variant.
Competing Interest Statement
M.S., F.B., S.S., S.D. and M.H. are inventors on a patent application on blocking antibodies against SARS-CoV-2. S.D. and M.H. are co-founders and shareholder of CORAT Therapeutics GmbH, a company founded for clinical and regulatory development of COR-101, an antibody for the treatment of hospitalized COVID-19 patients. S.D. and E.V.W. are co-founders and shareholders of Abcalis GmbH, a company producing antibodies for diagnostics of SARS-CoV-2.
Funding Statement
We kindly acknowledge the financial support of the European Union for the ATAC ("antibody therapy against corona," Horizon2020 number 101003650), the MWK Niedersachsen (14-76103-184 CORONA-2/20) for the projects "Antibody generation," "Neutralization experiments" and "Structure-based analysis of antiviral strategies against CoV-2 target proteins" and the Deutsche Herzstiftung ("Menschliche monoklonale Antikoerper gegen SARS-CoV2 zur Prophylaxe gegen COVID-19 bei vorerkrankten Risikopatienten - Unterstuetzung der Entwicklung") and the Swedish Research Council. SS was supported by DFG FOR3004. LCS was supported by grants from the Helmholtz Association (EU-Partering PIE-0008 and Helmholtz campaign COVIPA). We would like to thank all the blood donors who agreed to this scientific study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was given from the ethical committee of the Technische Universitaet Braunschweig (Ethik-Kommission der Fakultaet 2 der TU Braunschweig, approval number FV-2020-02) and the approval of the Ethical Commission of Hannover Medical School (Nr. 9254_BO_K_2020). The study in Italy was performed under the approval of the Institutional Review Board of Policlinico San Matteo (protocol number P_20200029440). The study in Sweden was approved by the ethics committee in Stockholm (Dnr 2020-02646).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Senior authors
- updated text according to reviewer comments for submission to BMC Medicine
Data Availability
All data produced in the present study are available upon reasonable request to the authors
